Moody's Foresees Junky Valeant Pharmaceuticals Deals

NEW YORK (TheStreet) -- Bond ratings firm Moody's isn't sold on the idea that the four largest generic drug manufacturers Teva Pharmaceuticals (TEVA), Mylan (MYL), Actavis (ACT) and Sandoz can continue to consolidate after years of merger activity in the sector. Moody's also would likely rate a takeover of any of the generics "big four" by serial acquirer Valeant Pharmaceuticals (VRX) as junk.

Will Valeant Overdose on Acquisitions?

Bausch + Lomb Success Less than Meets the Eye

"Mergers between any of the top four generic players would face significant challenges. The high level of fragmentation in the generic pharmaceutical industry and consolidation among its large customers argue for M&A among generic pharmaceutical players. But consolidation between the top four players --Teva Pharmaceutical, Mylan, Actavis plc, and Sandoz (owned by Novartis AG) -- is unlikely given antitrust challenges that would likely require significant divestitures," Moody's lead analyst Jessica Gladstone wrote in a Wednesday note.

The firm does see the prospect that Valeant Pharmaceuticals would go after one of the big four in the generics space, however, it said such a deal would likely be rated below investment grade.

"A hypothetical merger between Valeant and one of the top four generic players could be rated below investment grade. Given Valeant Pharmaceuticals' M&A appetite, we cannot completely rule out that it would buy a generic player," Moody's said.

A merger of a generic drug maker would be outside of Valeant's normal interest in specialty drug makers, Moody's noted. However, the company has recently indicated to the media and in investor presentations that it is bracing for a next big acquisition after buying Medicis and Bausch + Lomb in recent years.

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year